Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience
-
Moreira arrival completes MotoGP grid for 2026
-
Ancelotti warns Brazil to toughen up after defeat to Japan
-
Military seizes power in Madagascar as president impeached
-
French PM backs suspending pensions reform in key move for survival
-
Japan make waves with friendly win over Brazil
-
US Treasury chief accuses China of wanting to hurt world economy
-
IMF lifts 2025 global growth forecast, warns of ongoing trade 'uncertainty'
-
UN, Red Cross demand opening of all Gaza crossings to let in aid
-
Pakistan fancy chances as spinners run riot in South Africa Test
-
IMF raises 2025 global growth forecast on 'modest' US trade shock
-
Australia going into Ashes with 'worst team' since 2010: England great Broad
-
Europe's economic integration 'insufficient': IMF chief economist
-
Maria Grazia Chiuri named creative director at Fendi
-
Hamas forces back on Gaza streets as truce holds
-
Pakistan-South Africa Test finely poised after spinners run riot
-
French PM faces parliament in political crisis
-
Japan roar back in Tokyo to beat Brazil for first time
-
At secluded German airport, researchers tackle tricky drone defence
-
Agassi tips 'incredibly gifted' teenager Tien for the top
-
Fallen Austrian property tycoon Benko goes on trial over fraud charges
-
Tens of thousands march in Brussels against austerity plans
-
China sanctions five US units of South Korean ship giant Hanwha
-
Madagascar president hangs on to power as thousands protest
-
Barca's Lewandowski set to miss Clasico with hamstring injury
-
Ex-Premier League referee Coote admits making indecent image of child
-
Flights cancelled as Belgium hit by national strike
-
Harmer's double strike has Pakistan 36-2, lead South Africa by 145
-
Google to invest $15 bn in India, build largest AI hub outside US
-
Gill wins first series as India captain with 2-0 West Indies sweep
-
Monetochka: voice of resistance and hope for anti-Putin Russians
-
AI content proliferates in Hungary ahead of next year's elections
-
Guinea circus school offers a springboard for disadvantaged youth
-
Sting finds fractured modern music scene 'quite odd'
-
South Africa dismissed for 269 in reply to Pakistan's 378
-
Rahul hits half-century as India beat West Indies to sweep series
-
Trump tariffs on timber, furniture take effect
-
Honduras beat Haiti 3-0 to top World Cup qualifying group
-
Falcons beat Bills while Bears edge Commanders in NFL
-
Dodgers edge Brewers, Mariners rout Jays in MLB playoffs
-
Purrno Noir? New Zealand company sells non-alcoholic wine for pets
-
US threats cast doubt on shipping emissions deal
-
North Korean refugees long for family behind impenetrable border
-
Asian stocks pare tariff-led losses, Tokyo hit by political turmoil
-
Honduras beats Haiti for World Cup qualifying group lead
-
Venezuelan Nobel winner says Maduro will leave power 'with or without' talks
-
After uprising, Nepal's Gen Z rush to register to vote
-
SpaceX launches Starship megarocket on successful test flight
-
SpaceX's launches Starship megarocket on successful test flight
-
Four Brazilians to watch at COP30
-
Brazil's climate wins ahead of COP30
NYSE - LSE
| RBGPF | 0% | 75.55 | $ | |
| CMSC | 0.04% | 23.91 | $ | |
| AZN | -0.18% | 84.36 | $ | |
| NGG | 0.44% | 73.625 | $ | |
| SCS | -0.21% | 16.455 | $ | |
| GSK | 0.27% | 43.81 | $ | |
| BCC | -0.24% | 71.91 | $ | |
| RIO | -0.92% | 67.54 | $ | |
| RELX | 0.52% | 45.365 | $ | |
| VOD | 0.83% | 11.264 | $ | |
| BTI | 0.37% | 51 | $ | |
| RYCEF | -1.96% | 14.81 | $ | |
| JRI | -0.14% | 14.03 | $ | |
| BCE | -5.77% | 22.88 | $ | |
| CMSD | -0.55% | 24.167 | $ | |
| BP | -1.41% | 33.23 | $ |
Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience
FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced its Board of Directors has formally approved a strategic investment of $5 million in Bitcoin (BTC) as a strategic reserve asset. This move aligns with Sunshine Biopharma's broader strategy to strengthen its financial foundation while advancing its pipeline of generic prescription drugs and proprietary mRNA-based cancer therapies and antiviral drug candidates.
The Company's Bitcoin investment of $5 million will be executed over time through a regulated digital asset custodian or, the purchase of an ETF or a proxy stock. The Company plans to increase its holdings of Bitcoin by allocating additional funds as such funds become available in the future.
"We view Bitcoin not just as a hedge, but as a high-conviction asset with asymmetric upside," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "In an environment of persistent monetary expansion, Bitcoin offers a unique combination of scarcity, liquidity, and global accessibility. It's a natural complement to our long-term capital strategy."
The Company remains fully committed to its core mission of delivering life-saving therapeutics and will continue to focus on its drug development pipeline, including its antiviral small molecules, mRNA-based cancer therapies, and generic drug portfolio.
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 74 generic prescription drugs on the market in Canada and more than 12 additional drugs planned to be launched in 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire
Th.Berger--AMWN
